Branded

HDA recognizes pharmaceutical and consumer product manufacturers with DIANA honors
COLORADO SPRINGS, Colo. — The newly rebranded Healthcare Distribution Alliance on Tuesday recognized outstanding pharmaceutical and consumer product manufacturers with the annual Distribution Management Awards for Notable Achievements in Healthcare (DIANA).
FDA approves Espero Pharmaceuticals’ Gonitro sublingual powder
SILVER SPRING, Md. — The Food and Drug Administration has approved Espero Pharmaceuticals’ Gonitro (nitroglycerin), the company announced Tuesday. Gonitro is indicated to prevent or provide acute relief for an attack of angina pectoris due to coronary artery disease and it is available in single-dose packets of a short-acting nitrate in a stabilized crystal granule form.

HDMA rebranded as Healthcare Distribution Alliance
FDA approves first cholera prevention vaccine

SILVER SPRING, Md. — The Food and Drug Administration has approved Vaxchora, a single-dose oral vaccine for the prevention of cholera in adults aged 18 to 64 years, the vaccine maker PaxVax announced Monday. Vaxchora is the only cholera prevention vaccine approved by the FDA.
CDC: Despite extra month of flu, this season still mild compared to past three

ATLANTA - The Centers for Disease Control and Prevention on Friday noted that the 2015-2016 influenza season was lower in terms of influenza activity and peaked later as compared to the three previous seasons in the June 10 issue of the Morbidity and Mortality Weekly Report.

Activity remained low from October 2015 until late December 2015 and peaked in mid-March 2016. According to the report, only two other seasons have peaked in March in the past 18 influenza seasons - 2011–12 and 2005–06.
FDA OKs lower weight limit for HIV drug dolutegravir in children, adolescents

SILVER SPRING, Md. — The Food and Drug Administration has approved a reduced weight limit for children and adolescents with HIV-1 being treated with dolutegravir, ViiV Healthcare announced Friday.
FDA gives Upsher-Smith tentative approval for new Qudexy XR indication

SILVER SPRING, Md. — The Food and Drug Administration has granted tentative approval to Upsher-Smith Laboratories’ application for a new indication for its Qudexy XR (topiramate) extended-release capsules as a preventative therapy for migraine headaches.
Boehringer Ingelheim, HealthPrize team on Spiriva Respimat support program

RIDGEFIELD, Conn. — Boehringer Ingelheim on Wednesday announced a new online program for patients treating their COPD with the company’s Spiriva Respimat. The program, RespiPoints, is being undertaken in partnership with HealthPrize Technologies.
Takeda, Ultragenyx partner to develop rare genetic disease treatments

NOVATO, Calif. and OSAKA, Japan — Takeda on Tuesday announced a new partnership with Ultragenyx Pharmaceutical to develop and commercialize therapies for rare genetic diseases.
FDA approves Allergan’s Byvalson

SILVER SPRING, Md. — The Food and Drug Administration has approved Allergan’s Byvalson (nebivolol 5 mg and valsartan 80 mg) tablets, the company announced Monday. The drug is indicated to treat hypertension to lower blood pressure, and the company said it is the first fixed-dose combination of a beta-blocker and an angiotensin II receptor blocker in the U.S.

HDA recognizes pharmaceutical and consumer product manufacturers with DIANA honors

FDA approves Espero Pharmaceuticals’ Gonitro sublingual powder

HDMA rebranded as Healthcare Distribution Alliance

FDA approves first cholera prevention vaccine

CDC: Despite extra month of flu, this season still mild compared to past three

FDA OKs lower weight limit for HIV drug dolutegravir in children, adolescents

FDA gives Upsher-Smith tentative approval for new Qudexy XR indication

Boehringer Ingelheim, HealthPrize team on Spiriva Respimat support program

Takeda, Ultragenyx partner to develop rare genetic disease treatments

FDA approves Allergan’s Byvalson